



UNIVERSITY OF LEEDS

This is a repository copy of *Outcome measures in multimodal rectal cancer trials*.

White Rose Research Online URL for this paper:

<http://eprints.whiterose.ac.uk/160260/>

Version: Accepted Version

Article:

Fokas, E, Glynne-Jones, R, Appelt, A orcid.org/0000-0003-2792-9218 et al. (13 more authors) (2020) Outcome measures in multimodal rectal cancer trials. *Lancet Oncology*, 21 (5). e252-e264. ISSN 1470-2045

[https://doi.org/10.1016/S1470-2045\(20\)30024-3](https://doi.org/10.1016/S1470-2045(20)30024-3)

© 2020 Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Table 2. Primary clinical endpoint in randomised phase 2/3 trials of total neoadjuvant therapy with or without NOM option

Randomised phase 2 trials testing TNT	Patient number	Treatment schedule	Primary clinical endpoint
GCR-3 ⁶⁸	108	Capecitabine/Oxaliplatin CRT followed by surgery vs Induction CAPOX chemotherapy followed by Capecitabine/Oxaliplatin CRT and surgery	pCR
EXPERT-C ⁶⁹	165	Induction CAPOX chemotherapy + Cetuximab followed by Capecitabine/Cetuximab CRT and surgery vs CAPOX chemotherapy followed by Capecitabine CRT and surgery	cCR and pCR
GEMCAD 1402 ⁶⁰	115	Induction mFOLFOX6 chemotherapy + Aflibercept followed by Capecitabine CRT and surgery vs Induction mFOLFOX6 chemotherapy followed by Capecitabine CRT and surgery	pCR
GRECCAR4 ⁷⁰	194	Induction FOLFIRINOX followed by: -Good responders: immediate surgery vs Capecitabine CRT followed by surgery; -Poor responders: Capecitabine CRT (50 Gy) followed by surgery vs Capecitabine CRT (60 Gy) followed by surgery	R0 rate
CAO/ARO/AIO-12 ¹⁸	304	Induction mFOLFOX6 chemotherapy followed by 5-FU/Oxaliplatin CRT and surgery vs 5-FU/Oxaliplatin CRT followed by consolidation mFOLFOX6 chemotherapy and surgery	pCR
OPRA (NCT02008656)	300	Induction mFOLFOX6 chemotherapy followed by 5-FU CRT and surgery/NOM vs 5-FU CRT followed by consolidation mFOLFOX6 chemotherapy and surgery/NOM	3-year DFS
NRG GI002 (NCT02921256)		Induction FOLFOX chemotherapy followed by capecitabine CRT vs induction FOLFOX chemotherapy followed by capecitabine/Veliparib CRT vs induction FOLFOX chemotherapy followed by capecitabine/Pembrolizumab CRT	NAR
Randomised phase 2/3 trials testing NOM and LE/TEM	Patient number	Treatment schedule	Primary clinical endpoint
Brazilian trial (NCT02052921)	150	5-FU CRT followed by observation vs 5-FU CRT followed by TME surgery after achieving cCR at 12 weeks post CRT	3-year DFS
TESAR (NCT02371304)	302	TME surgery vs LE followed by capecitabine CRT	3-year LRR
OPERA (NCT02505750)	236	Capecitabine CRT followed by EBRT boost vs Capecitabine CRT followed by brachytherapy boost (if cCR: NOM or LE; if PR: TME)	3-year organ preservation [§]
WW3 (NCT04095299)	111	Capecitabine CRT vs Capecitabine CRT with SIB (if cCR: NOM or LE; if PR: TME)	2-year organ [§] preservation
MORPHEUS (NCT03051464)	40	Capecitabine CRT followed by EBRT boost vs Capecitabine CRT followed by brachytherapy boost (if cCR: NOM; if PR: TME)	2-year organ preservation

GRECCAR12 (NCT02514278)	218	mFOLFIRINOX followed by Capecitabine CRT vs Capecitabine CRT (if good response: LE; if poor response: TME)	12-month organ preservation [§]
TESS (NCT03840239)	168	Induction CAPOX chemotherapy followed by Capecitabine/Oxaliplatin CRT vs capecitabine/oxaliplatin CRT (if cCR: NOM; if PR: LE or TEM; if poor response: TME)	Sphincter preservation (stoma absence) at 18 months
STAR TREC (phase 2 part; NCT02945566)	120	TME surgery vs Capecitabine CRT followed by NOM vs SCRT followed by NOM (if cCR: NOM; if PR: TEM; if poor response: TME)	Recruitment rate at 12 and 24 months*
TREC (ISRCTN 14422743)	-	TME surgery vs SCRT followed by TEM and NOM	Recruitment rate at 12, 18 and 24 months*
APHRODITE (ISRCTN16158514)	104	5FU or capecitabine CRT vs 5FU or Capecitabine CRT with SIB (if cCR: NOM)	cCR rate at 6 months

[§]In the OPERA trial, organ preservation is defined as follows: the rate of rectum preservation either with local excision or watch and wait strategy after neoadjuvant treatment without non-salvageable locally progressive disease at 3 years post treatment, or permanent stoma. In the WW3 trial, organ preservation is defined as follows: rectum intact, no locoregional failure, no stoma at 2 years post-treatment

[§]In the GRECCAR12 trial, organ preservation is defined as follows: Number of patients with organ preservation and absence of stoma at 1 year after surgery.

*The aim of the studies is to assess the feasibility of recruitment within the phase 2 trial. If successful, the investigators will proceed into the phase 3 trial.

All trials shown above are phase 2, except the OPERA and GRECCAR12, which are randomised phase 3 trials; the MORPHEUS is a pilot randomised trial;

The Polish II, RAPIDO and ACO/ARO/AIO-18.1 phase 3 trials that evaluate(d) the concept of TNT are summarized in Table 3.

Abbreviations: pCR, pathological complete response, 5-FU, 5-Fluorouracil; CAPOX, capecitabine/oxaliplatin; FOLFOX, 5-FU, leukovorin, oxaliplatin; FOLFIRINOX, 5-FU, leukovorin, irinotecan, oxaliplatin; CRT, chemoradiotherapy; TME, total mesorectal excision; DFS, disease-free survival; LRR; locoregional recurrence; NOM, non-operative management; LE, local excision; TEM, transanal endoscopic microsurgery; PR, partial response; SCRT, short-course radiotherapy; W&W, watch and wait; SIB, simultaneously integrated boost;